Satellos to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF), a biotech company focused on developing small molecule therapeutics for muscle diseases, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The virtual conference will take place on February 11-12, 2025.
Co-founder and CEO Frank Gleeson will deliver a corporate presentation on February 11 at 1:20 p.m. ET and will join other management team members in one-on-one meetings throughout the conference. Investors can access the live webcast through the Events and Presentations page in the Investors section of Satellos' website, with a replay available after the presentation.
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF), una compagnia biotech focalizzata nello sviluppo di terapie a piccole molecole per malattie muscolari, ha annunciato la sua partecipazione alla 35a Conferenza Annuale sulle Scienze della Salute Oppenheimer. La conferenza virtuale si terrà l'11 e il 12 febbraio 2025.
Il cofondatore e CEO Frank Gleeson presenterà una relazione aziendale l'11 febbraio alle 13:20 ET e parteciperà a incontri individuali con altri membri del team di gestione durante tutta la conferenza. Gli investitori possono accedere alla diretta del webcast tramite la pagina Eventi e Presentazioni nella sezione Investitori del sito web di Satellos, con la possibilità di rivedere la presentazione dopo l'evento.
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF), una empresa biotecnológica enfocada en el desarrollo de terapias de pequeñas moléculas para enfermedades musculares, ha anunciado su participación en la 35ª Conferencia Anual de Ciencias de la Salud de Oppenheimer. La conferencia virtual se llevará a cabo el 11 y 12 de febrero de 2025.
El cofundador y CEO Frank Gleeson realizará una presentación corporativa el 11 de febrero a la 1:20 p.m. ET y se unirá a otros miembros del equipo directivo en reuniones uno a uno durante toda la conferencia. Los inversores pueden acceder a la transmisión en vivo a través de la página de Eventos y Presentaciones en la sección de Inversores del sitio web de Satellos, con una repetición disponible después de la presentación.
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF)는 근육 질환을 위한 소분자 치료제를 개발하는 바이오텍 회사로, 오펜하이머 제35회 연례 헬스케어 생명과학 컨퍼런스에 참여한다고 발표했습니다. 이번 온라인 회의는 2025년 2월 11일과 12일에 진행됩니다.
공동 창립자이자 CEO인 Frank Gleeson은 2월 11일 오후 1시 20분 ET에 기업 프레젠테이션을 진행하며, 컨퍼런스 기간 동안 다른 경영진들과 일대일 미팅에도 참석할 예정입니다. 투자자들은 Satellos 웹사이트의 투자자 섹션의 이벤트 및 프레젠테이션 페이지를 통해 실시간 웹캐스트에 접근할 수 있으며, 발표 후에는 재생할 수 있는 옵션이 제공됩니다.
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF), une entreprise biopharmaceutique spécialisée dans le développement de thérapies à petites molécules pour les maladies musculaires, a annoncé sa participation à la 35e Conférence Annuelle Oppenheimer sur les Sciences de la Santé. La conférence virtuelle se déroulera les 11 et 12 février 2025.
Le cofondateur et PDG Frank Gleeson présentera une intervention d'entreprise le 11 février à 13h20 ET et participera à des réunions individuelles avec d'autres membres de l'équipe de direction tout au long de la conférence. Les investisseurs peuvent accéder au webcast en direct via la page Événements et Présentations dans la section Investisseurs du site web de Satellos, avec une rediffusion disponible après la présentation.
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF), ein Biotechnologieunternehmen, das sich auf die Entwicklung von niedermolekularen Therapeutika für Muskelerkrankungen konzentriert, hat seine Teilnahme an der 35. jährlichen Oppenheimer Healthcare Life Sciences Konferenz bekannt gegeben. Die virtuelle Konferenz findet am 11. und 12. Februar 2025 statt.
Der Mitbegründer und CEO Frank Gleeson wird am 11. Februar um 13:20 Uhr ET eine Unternehmenspräsentation halten und wird während der gesamten Konferenz an Einzelgesprächen mit anderen Mitgliedern des Managementteams teilnehmen. Investoren können auf die Live-Übertragung über die Ereignis- und Präsentationsseite im Investorensegment der Satellos-Website zugreifen, mit einer Wiederholung, die nach der Präsentation verfügbar ist.
- None.
- None.
Mr. Frank Gleeson, Co-founder and CEO of Satellos, will provide a corporate presentation on Tuesday, February 11 at 1:20 p.m. ET and will participate in one-on-one meetings during the conference along with the management team of Satellos. The presentation will be available via live webcast on the Events and Presentations page in the Investors section of the Company’s website and a replay will be available following the presentation.
About Satellos Bioscience Inc.
Satellos is a clinical-stage drug development company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has invented SAT-3247 as a first-of-its-kind, orally administered small molecule drug designed to restore skeletal muscle regeneration initially in Duchenne muscular dystrophy (DMD). Satellos has generated a significant body of preclinical evidence in DMD to support its discovery that correcting muscle stem cell polarity with SAT-3247 has the potential to restore skeletal muscle regeneration to repair and strengthen muscle that has been damaged. The Company’s lead drug candidate, SAT-3247, is currently in clinical development as a potential disease-modifying treatment for DMD. Additionally, Satellos is leveraging its breakthrough research and proprietary discovery platform MyoReGenX™, to identify degenerative muscle diseases where deficits in muscle regeneration occur that are amenable to therapeutic intervention for future clinical development. For more information, visit www.satellos.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250204103858/en/
Investors: Liz Williams, CFO, ir@satellos.com
Media: Jessica Yingling, Ph.D., jessica@litldog.com
Source: Satellos Bioscience Inc.
FAQ
When is Satellos Bioscience (MSCLF) presenting at the Oppenheimer Healthcare Conference 2025?
How can investors watch Satellos Bioscience's (MSCLF) Oppenheimer conference presentation?
What is the format of Satellos Bioscience's (MSCLF) participation in the Oppenheimer conference?
What type of therapeutics is Satellos Bioscience (MSCLF) developing?
